Hepatitis C recurrence is not adversely affected by the use of donation after cardiac death liver allografts.
Tao
Ran
R
Thomas E. Starzl Transplantation Institute, University of Pittsburgh Medical Center, Pittsburgh, PA 15213, USA.
Ruppert
Kristine
K
Cruz
Ruy J
RJ
Malik
Shahid M
SM
Shaikh
Obaid
O
Ahmad
Jawad
J
DiMartini
Andrea
A
Humar
Abhinav
A
Fontes
Paulo A
PA
de Vera
Michael E
ME
D001706:Biopsy; D001926:Brain Death; D016022:Case-Control Studies; D005260:Female; D006084:Graft Rejection / Q000503:physiopathology / Q000821:virology; D006085:Graft Survival; D016174:Hepacivirus; D006526:Hepatitis C / Q000209:etiology* / Q000503:physiopathology / Q000601:surgery*; D006801:Humans; D007165:Immunosuppression Therapy; D008099:Liver / Q000473:pathology / Q000503:physiopathology / Q000601:surgery / Q000821:virology; D016031:Liver Transplantation / Q000009:adverse effects; D008297:Male; D008875:Middle Aged; D015999:Multivariate Analysis; D012008:Recurrence; D012307:Risk Factors; D014019:Tissue Donors; D014184:Transplantation, Homologous; D016896:Treatment Outcome